Cargando…

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level

SIMPLE SUMMARY: The activation of wild-type p53 protein in human lymphoma is a promising therapeutic strategy. A precise interruption of a protein–protein interaction, such as the p53-MDM2 interaction by nutlin-3a may lead lymphoma cells to apoptotic death through the stabilization and activation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Psatha, Konstantina, Kollipara, Laxmikanth, Drakos, Elias, Deligianni, Elena, Brintakis, Konstantinos, Patsouris, Eustratios, Sickmann, Albert, Rassidakis, George Z., Aivaliotis, Michalis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417430/ https://www.ncbi.nlm.nih.gov/pubmed/37568720 http://dx.doi.org/10.3390/cancers15153903

Ejemplares similares

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
por: Drakos, E, et al.
Publicado: (2011)

Proteomics and Drug Repurposing in CLL towards Precision Medicine
por: Mavridou, Dimitra, et al.
Publicado: (2021)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Subtyping on Live Lymphoma Cell Lines by Raman Spectroscopy
por: Katsara, Klytaimnistra, et al.
Publicado: (2022)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Nutlin‐3a selects for cells harbouring TP 53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016)

Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding Ribosomopathies
por: Papagiannopoulos, Christos I., et al.
Publicado: (2022)

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
por: Kaindl, U, et al.
Publicado: (2014)

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
por: Michaelis, M, et al.
Publicado: (2011)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol
por: Zajkowicz, Artur, et al.
Publicado: (2013)

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation
por: Zauli, Giorgio, et al.
Publicado: (2022)

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
por: Pechackova, Sona, et al.
Publicado: (2016)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
por: Lerma Clavero, Ada, et al.
Publicado: (2023)

Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
por: Gorgoulis, V. G., et al.
Publicado: (1998)

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
por: Ludwig, Michael P., et al.
Publicado: (2023)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
por: Lee, Dong Min, et al.
Publicado: (2017)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium
por: Markowski, Dominique N, et al.
Publicado: (2012)

Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein–protein interactions by the MDM2 ligand nutlin‐3
por: Way, Luke, et al.
Publicado: (2016)

Nutlin-3 downregulates p53 phosphorylation on serine(392) and induces apoptosis in hepatocellular carcinoma cells
por: Shi, Xinli, et al.
Publicado: (2014)

Disentangling thermal stress responses in a reef-calcifier and its photosymbionts by shotgun proteomics
por: Stuhr, Marleen, et al.
Publicado: (2018)

The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276
por: Li, Ruidong, et al.
Publicado: (2020)

The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro
por: Merches, Katja, et al.
Publicado: (2022)

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
por: Tokalov, Sergey V, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dqn7c18ishei476d57kq61d15g